Skip to main content
SpringerLink
Log in
Book cover

Atypical Breast Proliferative Lesions and Benign Breast Disease pp 89–102Cite as

Diagnostic Management of LCIS: Core Biopsy Alone Versus Core Biopsy plus Excision for Classic Versus Pleomorphic LCIS

  • Chapter
  • First Online:

  • 644 Accesses

Abstract

Lobular carcinoma in situ (LCIS) has traditionally been viewed first as precursor and then as a marker toward breast cancer development. Studies have reported that excisional biopsies of LCIS were associated with upgrade rates of 3.5–60% depending on subtypes (classic vs pleomorphic) and associated radiographic abnormality, resulting in increased rates of excisions and mastectomies. Hence, management of LCIS should be based on histological subtypes, concordant radiological-pathological findings, and clinical presentations. Emerging data support that patients with CLCIS can be managed with chemoprevention and surveillance. On the other hand, PLCIS should be managed similar to DCIS, with surgical excision with or without radiation.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   54.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   99.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   99.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

References

  1. Ewing J. Neoplastic diseases: a textbook on tumors. Philadelphia: W.B. Saunders; 1919.

    Google Scholar 

  2. Foote FW, Stewart FW. Lobular carcinoma in situ: a rare form of mammary cancer. Am J Pathol. 1941;17(4):491–6.

    CAS  PubMed  PubMed Central  Google Scholar 

  3. King TA, Reis-Filho J. Lobular carcinoma in situ: biology and management. In: Harris JR, Lippman ME, Morrow M, Osborn CK, editors. Diseases of the breast. 5th ed. Philadelphia: Lippincott Williams & Wilkins; 2014.

    Google Scholar 

  4. Portschy PR, Marmor S, Nzara R, et al. Trends in incidence and management of lobular carcinoma in situ: a population-based analysis. Ann Surg Oncol. 2013;20:3240–6.

    Article  PubMed  Google Scholar 

  5. King TA, Pilewskie M, Muhsen S, et al. Lobular carcinoma in situ: a 29-year longitudinal experience evaluating clinicopathologic features and breast cancer risk. J Clinic Oncol. 2015;33(33):3945–52.

    Article  Google Scholar 

  6. Ci L, Anderson BO, Porter P, et al. Changing incidence rate of invasive lobular breast carcinoma among older women. Cancer. 2000;88(11):2561–9.

    Article  Google Scholar 

  7. Lakhani SR, Ellis IO, Schnitt SJ, et al. WHO classification of tumours of the breast, vol. 4. Lyon: IARC Press; 2012.

    Google Scholar 

  8. Rosen PP, Kosloff C, Lieberman PH, et al. Lobular carcinoma in situ of the breast. Detailed analysis of 99 patients with average follow up of 24 years. Am J Surg Pathol. 1978;2(3):225–51.

    Article  CAS  PubMed  Google Scholar 

  9. Haagensen CD, Lane N, Lattes R, et al. Lobular neoplasia (so-called lobular carcinoma in situ) of the breast. Cancer. 1978;42(2):737–69.

    Article  CAS  PubMed  Google Scholar 

  10. Middleton LP, Sneige N, Coyne R, et al. Most lobular carcinoma in situ and atypical lobular hyperplasia diagnosed on core needle biopsy can be managed with radiologic follow-up in a multidisciplinary setting. Cancer Med. 2014;3(3):492–9.

    Article  PubMed  PubMed Central  Google Scholar 

  11. Shah V, Nowinski S, Levi D, et al. PIK3CA mutations are common in lobular carcinoma in situ, but are not a biomarker of progression. Breast Cancer Res. 2017;19(1):7.

    Article  PubMed  PubMed Central  Google Scholar 

  12. Aripno G, Allred DC, Mohsin SK, et al. Lobular neoplasia on core-needle biopsy: clinical significance. Cancer. 2004;101:242–50.

    Article  Google Scholar 

  13. Reis-Filho JS, Pinder SE. Non-operative breast pathology: lobular neoplasia. J Clin Pathol. 2007;60(12):1321–7.

    Article  PubMed  Google Scholar 

  14. Ginter P, D’Alfonos T. Current concepts in diagnosis, molecular features, and management of lobular carcinoma in situ of the breast with a discussion of morphologic variants. Arch Pathol Lab Med. 2017;141(12)1668–78.

    Article  Google Scholar 

  15. Dixon JM, Anderson TJ, Page DL, et al. Infiltrating lobular carcinoma of the breast. Histopathology. 1982;6:149–61.

    Article  CAS  PubMed  Google Scholar 

  16. Sullivan ME, Khan SA, Sullu Y, et al. Lobular carcinoma in situ variants in breast cores: potential for misdiagnosis, upgrade rates at surgical excisions, and practical implications. Arch Pathol Lab Med. 2010;134(7):1024–8.

    PubMed  Google Scholar 

  17. Khoury T, Karabakhtsian RG, Mattson D, et al. Pleomorphic lobular carcinoma in situ of the breast: clinicopathological review of 47 cases. Histopathology. 2014;64(70):981–93.

    Article  PubMed  PubMed Central  Google Scholar 

  18. Eusebi V, Magalhaes F, Azzopardi JG. Pleomorphic lobular carcinoma of the breast: an aggressive tumor showing apocrine differentiation. Hum Pathol. 1992;23:655–62.

    Article  CAS  PubMed  Google Scholar 

  19. Chaudhary S, Lawrence L, McGinty G, et al. Classic lobular neoplasia on core biopsy: a clinical and radio-pathologic correlation study with follow-up excision biopsy. Mod Pathol. 2013;26:762–71.

    Article  PubMed  Google Scholar 

  20. Sapino A, Frigerio A, Peterse JL, et al. Mammographically detected in situ lobular carcinomas of the breast. Virchows Arch. 2000;436:421–30.

    Article  CAS  PubMed  Google Scholar 

  21. Blanco LZ, Thurow TA, Mahajan A, et al. Multinucleation is an objective feature useful in the diagnosis of pleomorphic lobular carcinoma in situ. Am J Clin Pathol. 2015;144(5):772–26.

    Article  Google Scholar 

  22. Brogi E, Corhen A, Murray M. Morphologic precursor of mammary carcinoma and their mimics. Difficult diagnoses in breast pathology. Palazio JP. 2011. Demos Med. New York.

    Google Scholar 

  23. Chen YY, Hwang ES, Roy R, et al. Genetic and phenotypic characteristics of pleomorphic lobular carcinoma in situ of the breast. Am J Surg Pathol. 2009;33(11):1683–94.

    Article  PubMed  PubMed Central  Google Scholar 

  24. Shin S, Lal A, De Vries S, et al. Florid lobular carcinoma in situ: molecular profiling and comparison to classic lobular carcinoma in situ and pleomorphic lobular carcinoma in situ. Hum Pathol. 2012;44:1198–2009.

    Google Scholar 

  25. Mohsin SK, O’Connell PR, Allred DC, Libby AL. Biomarker profile and genetic abnormalities in lobular carcinoma in situ. Breast Cancer Res Treat. 2005;90(3):249–56.

    Article  PubMed  Google Scholar 

  26. Green AR, Krivinskas S, Young P, et al. Loss of expression of chromosome 16q genes DPEP1 and CTCF in lobular carcinoma in situ of the breast. Breast Cancer Res Treat. 2009;113(1):59–66.

    Article  CAS  PubMed  Google Scholar 

  27. Droufakou S, Deshmane V, Roylance R, et al. Multiple ways of silencing E cadherin gene expression in lobular carcinoma of the breast. Int J Cancer. 2001;92(3):404–8.

    Article  CAS  PubMed  Google Scholar 

  28. Sakr RA, Schiza M, Carniello JV, et al. Targeted capture massively parallel sequencing analysis of LCIS and invasive lobular cancer: repertoire of somatic genetic alterations and clonal relationships. Mol Oncol. 2016;10(2):360–70.

    Article  CAS  PubMed  Google Scholar 

  29. Andrade VP, Morrogh M, Qin LX, et al. Gene expression profiling of lobular carcinoma in situ reveals candidate precursor genes for invasion. Mol Oncol. 2015;9(4):772–82.

    Article  CAS  PubMed  Google Scholar 

  30. Carder PJ, Shaaban A, Alizadeh Y, Kumarasuwamy V, Liston JC, Sharma N. Screen-detected pleomorphic lobular carcinoma in situ (PLCIS): risk of concurrent invasive malignancy following a core biopsy diagnosis. Histopathology. 2010;57:472–8.

    Article  PubMed  Google Scholar 

  31. Chivukula M, Haynik DM, Brufsky A, et al. Pleomorphic lobular carcinoma in situ (PLCIS) on breast core needle biopsies: clinical significance and immune profile. Am J Surg Pathol. 2008;32:1721–6.

    Article  PubMed  Google Scholar 

  32. Fasola CE, Jensen KC, Horst KC. Local regional recurrence among patients with pleomorphic lobular carcinoma in situ: is there a role for radiation therapy? Int J Radiat Oncol Biol Phys. 2012;1:S238.

    Article  Google Scholar 

  33. Flanagan MR, Rendi MH, Calhoun KE, et al. Pleomorphic lobular carcinoma in situ: radiologic-pathologic features and clinical management. Ann Surg Oncol. 2015;22(13):4263–9.

    Article  PubMed  PubMed Central  Google Scholar 

  34. Hwang H, Barke LD, Mendelson EB, et al. Atypical lobular hyperplasia and classic lobular carcinoma in situ in core biopsy specimens: routine excision is not necessary. Mod Pathol. 2008;21:1208–16.

    Article  PubMed  Google Scholar 

  35. Morris K, Howe M, Kirwan C, et al. Clinical and phenotypic characteristics of core biopsy diagnosed pleomorphic lobular carcinoma-in-situ in a UK population (PLCIS). Eur J Surg Oncol. 2013;39:484.

    Article  Google Scholar 

  36. Niell B, Specht M, Gerade B, Rafferty E. Is excisional biopsy required after a breast core biopsy yields lobular neoplasia? AJR Am J Roentgenol. 2012;199:929–35.

    Article  PubMed  Google Scholar 

  37. Hussain M, Cunnick GH. Management of Lobular carcinoma in-situ and atypical lobular hyperplasia of the breast –a review. Eur J Surg Oncol. 2011;37(4):279–89.

    Article  CAS  PubMed  Google Scholar 

  38. Rendi MH, Dintzis SM, Lehman CD, et al. Lobular in-situ neoplasia on breast core needle biopsy: imaging indication and pathologic extent can identify which patients require excisional biopsy. Ann Surg Oncol. 2012;19(3):914–21.

    Article  PubMed  Google Scholar 

  39. Lewis JL, Lee DY, Tartter PI. The significance of lobular carcinoma in situ and atypical lobular hyperplasia of the breast. Ann Surg Oncol. 2012;19(13):4124–8.

    Article  PubMed  Google Scholar 

  40. Karabakhtsian RG, Johnson R, Sumkin J, et al. The clinical significance of lobular neoplasia on breast core biopsy. Am J Surg Pathol. 2007;31(5):717–23.

    Article  PubMed  Google Scholar 

  41. Pieri A, Harvey J, Bundred N. Pleomorphic lobular carcinoma in situ of the breast: can the evidence guide practice? World J Clin Oncol. 2014;4(3):546–53.

    Article  Google Scholar 

  42. Murray M, Brogi E. Lobular carcinoma in situ, classical type and unusual variants. Surg Pathol Clin. 2009;2:273–99.

    Article  PubMed  Google Scholar 

  43. Elsheikh TM, Silverman JF. Follow-up surgical excision is indicated when breast core needle biopsies show atypical lobular hyperplasia or lobular carcinoma in situ: a correlative study of 33 patients with review of the literature. Am J Surg Pathol. 2005;29(4):534–43.

    Article  PubMed  Google Scholar 

  44. Bevers TB, Anderson BO, Bonaccio E, et al. Breast cancer screening and diagnosis. J Nat Compr Netw. 2006;4(5):480–508.

    Article  Google Scholar 

  45. Port ER, Park A. Borgen pi, et al. results of MRI screening for breast cancer in high-risk patients with LCIS and atypical hyperplasia. Ann Surg Oncol. 2007;14(3):1051–7.

    Article  PubMed  Google Scholar 

  46. King TA, Muhsen S, Patil S, et al. Is there a role for routine screening MRI in women with LCIS? Breast Cancer Res Treat. 2013;142(2):445–53.

    Article  PubMed  Google Scholar 

  47. Fisher B, Costantino JP, Wickerham DL, et al. Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP study of tamoxifen and raloxifene (STAR) P-2 trial. JAMA. 2006;295(23):2727–41.

    Article  Google Scholar 

  48. Coopey SB, Mazzola E, Buckley JM, et al. The role of chemoprevention in modifying the risk of breast cancer in women with atypical breast lesions. Breast Cancer Res Treat. 2012;136:627–33.

    Article  CAS  PubMed  Google Scholar 

  49. Visvanathan K, Hurely P, Bantug E, et al. Use of pharmacologic interventions for breast cancer risk reduction: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol. 2013;31:2942–62.

    Article  PubMed  Google Scholar 

  50. Ropka ME, Keim J, Philbrik JT. Patient decisions about breast cancer chemoprevention: a systematic review and meta-analysis. J Clin Oncol. 2009;28(18):3090–5.

    Article  Google Scholar 

  51. Cuzick J, Sestak I, Cawathorn S, Hamed H, Holli K, Howell A, et al. Tamoxifen for prevention of breast cancer: extended long-term follow-up of the IBIS0I breast cancer prevention trial. Lancet Oncol. 2015;16:67–75.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  52. Wong S, King TA, Boileau JF, et al. Population-based analysis of breast cancer incidence and survival outcomes in women diagnosed with lobular carcinoma in situ. Ann Surg Oncol. 2017 Sep;24(9):2509–17.

    Article  PubMed  Google Scholar 

  53. Downs-Kelly E, Bell D, Sneige N, et al. Management of pleomorphic lobular carcinoma in situ (supplement 1): Abstract no. 119:29A. Modern Pathology 2008; 97th Annual Meeting of United States and Canadian Academy of Pathology, March 1–7, Denver.

    Google Scholar 

  54. Ciocca RM, Li T, Freedman GM, et al. Presence of lobular carcinoma in situ does not increase local recurrence in patients treated with breast-conservation therapy. Ann Surg Oncol. 2008;15(8):2263–71.

    Article  PubMed  PubMed Central  Google Scholar 

  55. Middleton LP, Grant S, et al. Lobular Carcinoma In Situ Diagnosed By Core Needle Biopsy: When Should It Be Excised? Modern Pathology 2003;16(2):120–129.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Lynn Sage Comprehensive Breast Center, Chicago, IL, USA

    Batul Al-zubeidy & Nora Hansen

Authors
  1. Batul Al-zubeidy
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Nora Hansen
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Nora Hansen .

Editor information

Editors and Affiliations

  1. Samuel Oschin Comprehensive Cancer Inst, Cedars-Sinai Medical Center, Los Angeles, CA, USA

    Farin Amersi

  2. School of Medicine, University of Washington School of Medicine, Seattle, WA, USA

    Kristine Calhoun

Rights and permissions

Reprints and permissions

Copyright information

© 2018 Springer International Publishing AG, part of Springer Nature

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Al-zubeidy, B., Hansen, N. (2018). Diagnostic Management of LCIS: Core Biopsy Alone Versus Core Biopsy plus Excision for Classic Versus Pleomorphic LCIS. In: Amersi, F., Calhoun, K. (eds) Atypical Breast Proliferative Lesions and Benign Breast Disease . Springer, Cham. https://doi.org/10.1007/978-3-319-92657-5_7

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-92657-5_7

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-92656-8

  • Online ISBN: 978-3-319-92657-5

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation